Genprex Inc. announced that it has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, as confirmed in a letter from Nasdaq's Listing Qualifications Department on June 6, 2025. Previously, the company had been notified in November 2024 that it was not meeting the minimum stockholders' equity of $2.5 million. However, based on Genprex's recent quarterly report, Nasdaq has confirmed that the company now meets the necessary requirements, resolving the prior issue. Additionally, Genprex is working to address another compliance matter regarding the minimum bid price of its common stock, which remains below the required $1.00 per share. The company has until August 6, 2025, to rectify this situation and is considering strategies such as a reverse stock split to meet Nasdaq's standards.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.